In the development of modern drug delivery systems, liposomes have become one of the core carriers due to their excellent biocompatibility and wide drug loading range. Breakthroughs in nanoscale emulsification technology have greatly unleashed the application potential of liposomes. This technology, by precisely controlling the particle size of the lipid dispersion phase to the nanoscale, solves key problems in traditional drug delivery such as low solubility, poor targeting, and strong side effects, providing important technical support for precision medicine.
The core principle of liposome nanoscale emulsification lies in utilizing the amphiphilic characteristics of phospholipids. Through a specific process, lipid molecules are oriented at the oil-water interface to form thermodynamically stable nanoscale vesicle structures. The hydrophilic ends of phospholipid molecules face the aqueous phase, and the hydrophobic ends face the oil phase, spontaneously assembling into a bilayer membrane. This encapsulates hydrophilic or hydrophobic drugs within the core aqueous phase or lipid bilayer, achieving efficient loading of drugs with different properties. This process requires strict control of interfacial tension and steric hindrance. Through the appropriate ratio of surfactants and the application of external forces, the dispersed phase particle size must be uniformly distributed within the 10-100 nanometer range to ensure the stability and bioactivity of the liposomes.
Currently, mainstream nanoscale emulsification preparation technologies include high-pressure homogenization, microfluidics, and ultrasonic emulsification. High-pressure homogenization forcibly compresses the pre-emulsified system through a micrometer-level narrow slit, utilizing shear stress and turbulence to break down particles; after multiple cycles, uniformly sized nanoliposomes can be obtained. Microfluidics utilizes precise channels to achieve accurate mixing of the oil and water phases, enabling the preparation of nanoformulations with smaller particle size deviations. Ultrasonic emulsification utilizes cavitation to instantaneously break down oil droplets, offering advantages of ease of operation and low cost. Regardless of the technology, the core objectives are to achieve narrow particle size distribution, high encapsulation efficiency, and good biocompatibility.
Nanoscale emulsification endows liposome carriers with multiple significant advantages. First, the nanoscale particle size enhances drug bioavailability, particularly improving the solubility of poorly soluble drugs, while reducing the first-pass effect in the liver and gastrointestinal degradation. Second, nanoliposomes can accumulate in lesion tissues through passive targeting and enhanced permeability retention, or achieve active targeting through surface modification, increasing drug concentration at the lesion site and reducing toxic side effects on normal tissues. Third, the nanostructure protects drugs from degradation by the biological environment, achieving long-lasting release and reducing the frequency of administration. These advantages make them promising for applications in anti-tumor, anti-inflammatory, and antibacterial fields, and several nanoliposome formulations have already been approved for clinical use.
With continuous technological iteration, the nanoscale emulsification of liposomes will develop towards more precise particle size control, higher drug loading efficiency, and intelligent responsive release. In the future, through process optimization and material innovation, this technology is expected to further overcome mass production bottlenecks, driving more efficient and safe nano-drug-loaded formulations to clinical applications and bringing new breakthroughs to the treatment of complex diseases.
